Search Results - multiple+cns+indications

5 Results

Sort By:

Intranasal Administration of Glutamate Carboxypeptidase (GCP-II) Inhibitors for Enhanced Brain Delivery

Inventors have developed a novel method to enhance the penetrance of multiple GCPII inhibitors which were developed by the inventor and Dr. Pomper at JHU. This method demonstrated improved brain penetrance in rodents. The penetrance of a specific GCPII inhibitor showed significant brain penetrance in non-human primates and inhibited GCPII activity in...

Published: 3/13/2025 | Inventor(s): Rana Rais, Barbara Slusher

Keywords(s): Biologics, CNS and Neurological Disorders, Disease Indication, Drug Delivery Mechanism, Enzyme, Imaging Agent, Imaging and Sensing Systems, Imaging Modality, In Vivo Medical Imaging, Intranasal Administration, Multiple CNS Indications, Positron Emission Tomography (PET), Therapeutic Matter, Therapeutic Substance, Therapeutics

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Neurology, Technology Classifications > Medical Devices > Imaging, Technology Classifications > Therapeutic Modalities > Biologics, Technology Classifications > Therapeutic Modalities > Proteins, Technology Classifications > Therapeutic Modalities > Therapeutic Delivery Platforms, Technology Classifications > Medical Devices, Technology Classifications > Therapeutic Modalities

Quantitation of GCPII Enzymatic Activity in Human Skin Biopsies as a Clinical Biomarker

We have identified a unique tissue preparation and enzymatic assay conditions to quatitatively monitor glutamate carboxypeptidase II (GCPII) activity in human skin biopsy samples. This assay can be utilzed as a phanacodynamic (PD) marker in the clinical development of novel GCPII inhibitors. This new assay is a significant improvement over GCPII biomarker...

Published: 3/13/2025 | Inventor(s): Barbara Slusher, Camilo Rojas, Marigo Stathis, Michael Polydefkis

Keywords(s): Assay, Biomarker, Clinical Diagnostics, CNS and Neurological Disorders, Disease Indication, In Vitro Diagnostics, Multiple CNS Indications, Pharmakodynamic Biomarker, Therapeutic Matter, Therapeutics

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Neurology, Technology Classifications > Diagnostics > Biomarkers, Technology Classifications > Diagnostics > In Vitro Diagnostics, Technology Classifications > Therapeutic Modalities > Targets, Technology Classifications > Diagnostics, Technology Classifications > Therapeutic Modalities

Novel inhibitors of protein kinase signaling that are neuroprotective and have potential applicability for the treatment of glaucoma, optic nerve disease, and other forms of neurodegeneration - #2

Glaucoma is a major cause of visual loss and blindness in elderly Americans and throughout the world. One approach to treatment of glaucoma, and other optic nerve diseases as well as other neurodegenerations, is to develop neuroprotective agents that promote the survival of neurons. Through a high content screen of libraries of small molecule compounds,...

Published: 3/13/2025 | Inventor(s): Laszlo Hackler, Dana Ferraris, Cynthia Berlinicke, James Inglese, Tomas Vojkovsky, Joseph Steiner, Barbara Slusher, Zhiyong Yang, Donald Zack

Keywords(s): Antagonists/Inhibitors, CNS and Neurological Disorders, Disease Indication, Eye Disorders, Multiple CNS Indications, Novel, Predicted Novelty, Small Molecules, Therapeutic Matter, Therapeutic Substance, Therapeutics

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Neurology, Clinical and Disease Specializations > Ophthalmology, Technology Classifications > Therapeutic Modalities > Small Molecules, Technology Classifications > Therapeutic Modalities

C11355: Therapeutic Alleviating Cognitive Impairment from Multiple Sclerosis (MS)

Novelty:This technology is a first of its kind, potential therapeutic in alleviating cognitive impairment (CI) as a result of Multiple Sclerosis (MS) and related central nervous system (CNS) autoimmune diseases.Value Proposition:CI is a debilitating outcome of many CNS disorders, including MS. Currently, the high prevalence of CI and the extremely negative...

Published: 3/13/2025 | Inventor(s): Barbara Slusher, Kristen Hollinger, Adam Kaplin

Keywords(s): Antagonists/Inhibitors, Biomarker, Clinical Diagnostics, CNS and Neurological Disorders, Cognitive Impairment, Diagnostic Biomarker, Disease Indication, In Vitro Diagnostics, Mechanism of Action Biomarker, Multiple CNS Indications, Non-novel, Predicted Novelty, Repurposed, Small Molecules, Target, Therapeutic Matter, Therapeutic Substance, Therapeutics

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Neurology, Clinical and Disease Specializations > Neurology > Cognitive Impairment, Technology Classifications > Diagnostics > Biomarkers, Technology Classifications > Diagnostics > Diagnostic Biomarkers, Technology Classifications > Diagnostics > In Vitro Diagnostics, Technology Classifications > Therapeutic Modalities > Small Molecules, Technology Classifications > Therapeutic Modalities > Targets, Technology Classifications > Diagnostics, Technology Classifications > Therapeutic Modalities

Role of Limonoid Compounds As Neuroprotective Agents

Invention novelty: A series of compounds from the limonoid family that can be used in protecting neurons from different types of toxicity. Unmet Need: Neurodegenerative diseases are characterized by extensive deterioration of neurons or glia. Because these cells are not easily regenerated, there is an emerging unmet medical need for a therapeutic...

Published: 3/13/2025 | Inventor(s): Norman Haughey, Avindra Nath, Joseph Steiner

Keywords(s): CNS and Neurological Disorders, Disease Indication, Multiple CNS Indications, Natural compounds, Neurodegeneration, Neurodegenerative Diseases, Non-novel, Predicted Novelty, Small Molecules, Therapeutic Matter, Therapeutic Substance, Therapeutics

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Neurology, Clinical and Disease Specializations > Neurology > Neurodegeneration, Technology Classifications > Therapeutic Modalities > Small Molecules, Technology Classifications > Therapeutic Modalities